|
Nov 8
|
Gilead Sciences Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Nov 7
|
Gilead Sprints To A Profit-Taking Zone After Riding Covid Drug To Beat And Raise
|
|
Nov 7
|
HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook
|
|
Nov 7
|
Gilead increases 2024 outlook, expects new drug filing by end of year
|
|
Nov 7
|
Gilead Beats on Q3 Earnings and Sales, Raises Annual Outlook
|
|
Nov 7
|
Q3 2024 Gilead Sciences Inc Earnings Call
|
|
Nov 7
|
Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic
|
|
Nov 7
|
Gilead Sciences Inc (GILD) Q3 2024 Earnings Call Highlights: Strong HIV and Oncology Sales ...
|
|
Nov 7
|
Gilead Sciences (GILD) Q3 2024 Earnings Call Transcript
|
|
Nov 6
|
Gilead (GILD) Reports Q3 Earnings: What Key Metrics Have to Say
|
|
Nov 6
|
Gilead Sciences (GILD) Q3 Earnings and Revenues Surpass Estimates
|
|
Nov 6
|
Gilead 3rd-quarter results beat Wall Street estimates, raises outlook
|
|
Nov 6
|
Gilead: Q3 Earnings Snapshot
|
|
Nov 6
|
Gilead Sciences Announces Third Quarter 2024 Financial Results
|
|
Nov 6
|
Top 20 biopharmas’ market cap rises 2% in Q3 2024 amid flurry of drug approvals
|
|
Nov 5
|
Kite to Highlight Industry-Leading CAR T-Cell Therapy Portfolio at ASH 2024, Including Positive Survival Outcomes in Both Clinical Trials and the Real-World
|
|
Nov 4
|
Is Gilead Sciences, Inc. (GILD) the Best Pharma Stock to Buy Right Now?
|
|
Nov 1
|
Stocks to watch this week: Berkshire Hathaway, Super Micro, Novo Nordisk, Vistry and M&S
|
|
Oct 24
|
3 Absurdly Cheap Stocks That Pay High Dividends
|
|
Oct 23
|
Why Gilead Sciences (GILD) Dipped More Than Broader Market Today
|